This analysis examines the historical and forecast performance for Barr in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Key reasons to purchase this research - Benchmark Barr's performance against key rivals in the prescription pharmaceutical sector - Assess the future commercial potential of Barr in light of its impending acquisition by Teva, due to be completed in late 2008/early 2009 - Analyze Barr's leading position in the global market for generic oral contraceptive products
